181 related articles for article (PubMed ID: 33563649)
1. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract][Full Text] [Related]
2. Circulating inflammation markers and prospective risk for lung cancer.
Shiels MS; Pfeiffer RM; Hildesheim A; Engels EA; Kemp TJ; Park JH; Katki HA; Koshiol J; Shelton G; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2013 Dec; 105(24):1871-80. PubMed ID: 24249745
[TBL] [Abstract][Full Text] [Related]
3. Prolactin and Risk of Epithelial Ovarian Cancer.
Hathaway CA; Rice MS; Townsend MK; Hankinson SE; Arslan AA; Buring JE; Hallmans G; Idahl A; Kubzansky LD; Lee IM; Lundin EA; Sluss PM; Zeleniuch-Jacquotte A; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1652-1659. PubMed ID: 34244157
[TBL] [Abstract][Full Text] [Related]
4. Circulating inflammation markers and risk of epithelial ovarian cancer.
Clendenen TV; Lundin E; Zeleniuch-Jacquotte A; Koenig KL; Berrino F; Lukanova A; Lokshin AE; Idahl A; Ohlson N; Hallmans G; Krogh V; Sieri S; Muti P; Marrangoni A; Nolen BM; Liu M; Shore RE; Arslan AA
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):799-810. PubMed ID: 21467242
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides.
Trabert B; Hathaway CA; Rice MS; Rimm EB; Sluss PM; Terry KL; Zeleznik OA; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Nov; 30(11):2044-2051. PubMed ID: 34404683
[TBL] [Abstract][Full Text] [Related]
6. Urinary PGE-M Levels and Risk of Ovarian Cancer.
Barnard ME; Beeghly-Fadiel A; Milne GL; Akam EY; Chan AT; Eliassen AH; Rosner BA; Shu XO; Terry KL; Xiang YB; Zheng W; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2019 Nov; 28(11):1845-1852. PubMed ID: 31387969
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.
Zeleznik OA; Eliassen AH; Kraft P; Poole EM; Rosner BA; Jeanfavre S; Deik AA; Bullock K; Hitchcock DS; Avila-Pacheco J; Clish CB; Tworoger SS
Cancer Res; 2020 Mar; 80(6):1357-1367. PubMed ID: 31969373
[TBL] [Abstract][Full Text] [Related]
8. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.
Peres LC; Mallen AR; Townsend MK; Poole EM; Trabert B; Allen NE; Arslan AA; Dossus L; Fortner RT; Gram IT; Hartge P; Idahl A; Kaaks R; Kvaskoff M; Magliocco AM; Merritt MA; Quirós JR; Tjonneland A; Trichopoulou A; Tumino R; van Gils CH; Visvanathan K; Wentzensen N; Zeleniuch-Jacquotte A; Tworoger SS
Cancer Res; 2019 Oct; 79(20):5442-5451. PubMed ID: 31462430
[TBL] [Abstract][Full Text] [Related]
9. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Pinto L; Hartge P; Kemp T; Black A; Sherman ME; Brinton LA; Pfeiffer RM; Shiels MS; Chaturvedi AK; Hildesheim A; Wentzensen N
Gynecol Oncol; 2014 Nov; 135(2):297-304. PubMed ID: 25158036
[TBL] [Abstract][Full Text] [Related]
10. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
Tworoger SS; Lee IM; Buring JE; Rosner B; Hollis BW; Hankinson SE
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):783-8. PubMed ID: 17416771
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai.
Shiels MS; Shu XO; Chaturvedi AK; Gao YT; Xiang YB; Cai Q; Hu W; Shelton G; Ji BT; Pinto LA; Kemp TJ; Rothman N; Zheng W; Hildesheim A; Lan Q
Carcinogenesis; 2017 Oct; 38(10):1004-1010. PubMed ID: 28981818
[TBL] [Abstract][Full Text] [Related]
12. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study.
Zeleznik OA; Clish CB; Kraft P; Avila-Pacheco J; Eliassen AH; Tworoger SS
J Natl Cancer Inst; 2020 Jun; 112(6):628-636. PubMed ID: 31593240
[TBL] [Abstract][Full Text] [Related]
13. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Eldridge RC; Pfeiffer RM; Shiels MS; Kemp TJ; Guillemette C; Hartge P; Sherman ME; Brinton LA; Black A; Chaturvedi AK; Hildesheim A; Berndt SI; Safaeian M; Pinto L; Wentzensen N
Int J Cancer; 2017 Feb; 140(3):600-610. PubMed ID: 27770434
[TBL] [Abstract][Full Text] [Related]
14. Prediagnostic Proinflammatory Dietary Potential Is Associated with All-Cause Mortality among African-American Women with High-Grade Serous Ovarian Carcinoma.
Peres LC; Hebert JR; Qin B; Guertin KA; Bandera EV; Shivappa N; Camacho TF; Chyn D; Alberg AJ; Barnholtz-Sloan JS; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Schildkraut JM
J Nutr; 2019 Sep; 149(9):1606-1616. PubMed ID: 31152675
[TBL] [Abstract][Full Text] [Related]
15. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk.
McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Kaaks R; Rinaldi S; Helzlsouer KJ
Int J Cancer; 2009 Aug; 125(3):674-9. PubMed ID: 19444906
[TBL] [Abstract][Full Text] [Related]
16. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.
Barnard ME; Poole EM; Curhan GC; Eliassen AH; Rosner BA; Terry KL; Tworoger SS
JAMA Oncol; 2018 Dec; 4(12):1675-1682. PubMed ID: 30286239
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.
Poole EM; Lee IM; Ridker PM; Buring JE; Hankinson SE; Tworoger SS
Am J Epidemiol; 2013 Oct; 178(8):1256-64. PubMed ID: 23966559
[TBL] [Abstract][Full Text] [Related]
18. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein concentrations and subsequent ovarian cancer risk.
McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Pollak M; Tao Y; Helzlsouer KJ
Obstet Gynecol; 2007 Apr; 109(4):933-41. PubMed ID: 17400857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
